Stifel lowered the firm’s price target on Bruker (BRKR) to $57 from $70 and keeps a Hold rating on the shares. Bruker continues to show ...

Barclays lowered the firm’s price target on Bruker (BRKR) to $60 from $65 and keeps an Overweight rating on the shares. The firm sees elevated ...

Bruker expects full-year earnings in the range of $2.67 to $2.72 per share, with revenue in the range of $3.47 billion to $3.54 billion. Bruker shares have fallen 12% since the beginning of the year.

Bruker's minispec Whole Body Composition Analyzer based on TD-NMR provides a precise method for measurement of lean tissue, fat and fluid in living mice and rats. This body composition analyzer ...

timsTOF was engineered by Bruker experts as an open platform to accelerate the adoption of ion mobility-mass spectrometry analysis across research applications. All that is missing are your ...

Discover key takeaways from Bruker Corporation's Q4 2024 earnings call, highlighting strong diagnostics, semiconductor growth, and confident 2025 ...

BILLERICA, Mass. - Bruker Corporation (NASDAQ:BRKR) reported fourth-quarter earnings that surpassed analyst expectations, while also providing a 2025 outlook largely in line with Wall Street estimates ...

Corporation reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of $0.76 against the forecast of $0.74. Revenue also exceeded projections, ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the ...

Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of ...

Scientific instrument company Bruker Corp. acquired NanoString in May for $392.6 million, ending bankruptcy proceedings but reopening the company to patent litigation. Gray and former NanoString ...